Company intelligence / Profile preview

J&X

Shanghai, China

Ownership: Private
Development stage: Other

Overview

J&X Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule therapeutics for oncology and infectious diseases. The company leverages its proprietary drug discovery platform to target well-validated but difficult-to-drug pathways, such as KRAS and BTK. Its lead programs include JX-0759, a potent KRAS G12C inhibitor, and JX-0853, a next-generation BTK inhibitor designed to overcome resistance. Headquartered in Shanghai with R&D operations in the United States, J&X aims to address significant unmet medical needs in global markets. The company is backed by prominent venture capital firms including Sequoia China and Matrix Partners China.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on J&X.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on J&X.

Explore the full profile